Dronedarone: A novel antiarrhythmic agent for the treatment of atrial fibrillation

Current Opinion in Cardiology

Volumn 25, Issue 1, 2010, Pages 53-58

  Duray, Gabor Z ^a   Ehrlich, Joachim R ^a   Hohnloser, Stefan H ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Dronedarone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATROPINE; CREATININE; CYTOCHROME P450 3A4; DIGOXIN; DRONEDARONE; LIDOCAINE; PLACEBO; POTASSIUM CHANNEL; SODIUM CHANNEL; SOTALOL;

ADRENERGIC RECEPTOR BLOCKING; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; BRADYCARDIA; CARDIOVERSION; CHANNEL GATING; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART RATE; HEART VENTRICLE FIBRILLATION; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; LUNG DISEASE; MORTALITY; NAUSEA; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; THYROID DISEASE; TORSADE DES POINTES; VASODILATATION;

ADRENERGIC ANTAGONISTS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; ION CHANNELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS;

EID: 74249117312     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833354e4     Document Type: Review

References (28)

1. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999. Implications for primary prevention. Circulation 2003; 108:711-716.
2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114: 700-752.
3. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow up. Heart Rhythm 2007; 4:1-46.
4. Singh BN, Singh SN, Reda DJ, et al. Sotalol amiodarone atrial fibrillation efficacy trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861-1872.
5. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007; 356:935-941.
6. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 1999; 100:2276-2281.
7. Gautier P, Guillemare E, Marion A, et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol 2003; 41:191-202.
8. Varro A, Takacs J, Nemeth M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol 2001; 133:625-634.
9. + current, HERG and KvLQT1/ min K potassium channels. Br J Pharmacol 2003; 140:996-1002.
10. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Circulation 1990; 81:686-690.
11. 2+ current. Circ Res 1989; 64:977-990.
12. Makielski JC, January CT. Proarrhythmia related to prolongation of repolarization: mechanisms, monitoring, prevention and management. Cardiac Electrophysiol Rev 1998; 2:132-135.
13. Lalevee N, Nargeot J, Barrere-Lemaire S, et al. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 2003; 14:885-890.
14. Altomare C, Barbuti A, Viscomi C, et al. Effects of dronedarone on acetylcholine- activated current in rabbit San cells. Br J Pharmacol 2000; 130: 1315-1320.
15. + current in guinea pig atrial cells. J Cardiovasc Pharmacol 2000; 36:802-805.
16. Chatelain P, Meysmans L, Mateazzi JR, et al. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the b2-adrenoceptor and adenylate cyclase in the rat heart. Br J Pharmacol 1995; 116:1949-1956.
17. Hodeige D, Heyndrickz JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: antiadrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol 1995; 279:25-32.
18. Finance O, Manning A, Chatelain P. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 1995; 26:570-576.
19. Manning AS, Bruynickx C, Ramboux J, Chatelain P. SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995; 26:453-461.
20. Zarebra KM. Dronedarone: a new antiarrhythmic agent. Drugs Today 2006; 42:75-86.
21. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003; 24:1481-1487.
22. Singh BN, Connolly SJ, Crijns HJ, et al., EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987-999.
23. Davy JM, Herold M, Hoglund C, et al., ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008; 156:527 e1-527 e9.
24. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678-2687.
25. Solomon SC, Dobson J, Pocock S, et al., for the CHARM Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116:1482-1487.
26. Hohnloser SH, Connolly SJ, Crijns HJ, et al. Rationale and design of ATHENA: a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol 2008; 19:69-73.
27. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668-678.
28. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al., ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallelarm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009; 120:1174-1180.